Positioning of Esketamine Treatment in the Real-world Management of Depression

Major Depressive Disorder Clinical Trial

— PoET  

Official title:

Positioning of Esketamine Treatment in the Real-world Management of Depression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06103760
• Other study ID #: 2023/PID01587
• Status: Recruiting
• Phase: Phase 4
• Start date: October 31, 2023
• Est. completion date: January 15, 2026

Study information

• Verified date: May 2024
• Source: Royal North Shore Hospital
• Contact: Erica Bell
• Phone: 02 9462 9905
• Email: NSLHD-researchpoet[@]health.nsw.gov.au
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are:

• to investigate whether Esketamine is effective when added to ongoing antidepressant treatment

• to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice

Participants will:

• attend the clinic for supervised self-administration of intranasal Esketamine treatment

• be observed for 2 hours following Esketamine administration including blood pressure monitoring

• be asked to complete a battery of questionnaires

• be reimbursed for travel expenses

Description:

Depression is a common mental illness, and it is one of the leading causes of disease burden worldwide. Fortunately, there are many effective treatments available for depression, including lifestyle changes, psychological treatments, and medications such as antidepressants. However, not all patients will respond to the first treatment prescribed. Some patients may only experience a 'partial response', where a few treatments help their depression somewhat, but they do not achieve a full recovery. Currently, the reasons why some patients do not respond, or only experience a partial response to an antidepressant, is not fully understood.

Recently, researchers have been investigating new medications that may help patients recover from depression. One of these new medications is Esketamine, which is a relatively new molecule derived from a drug called Ketamine - an anaesthetic that has been used medically for decades. Researchers have been investigating the antidepressant properties of Ketamine for a long time. It is thought that Ketamine, and its derivative, Esketamine, help to treat depression for a number of reasons. However, it is not yet known which patients benefit most from Esketamine when used in conjunction with conventional antidepressants. In addition, we do not yet understand how the effect of Esketamine is impacted by other treatments that a patient may be taking for their depression. Finally, it has not yet been investigated how patients with a partial response to an antidepressant will benefit from adding Esketamine to their therapeutic regimen without switching to a new baseline antidepressant. Therefore, there are two principle aims of this study 1) to investigate whether Esketamine is effective when added to ongoing antidepressant treatment and 2) to identify patient characteristics that will determine a therapeutic response to Esketamine in real-world practice.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 162
• Est. completion date: January 15, 2026
• Est. primary completion date: September 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adults aged 18-65 years old

2. Diagnosis of Major Depressive Disorder (MDD)

3. Currently depressed

4. Had an inadequate response to 2 or more courses of antidepressants (of adequate dose and duration)

5. Be maintained on their current antidepressant medication or psychological therapy at the time of enmrolment

6. Able to understand and provide informed consent

Exclusion Criteria:

1. Concurrent diagnoses:

• Participants with other 'Diagnostic and Statistical Manual of Mental Disorders' (DSM-5) e.g., current substance misuse disorder, bipolar disorder, schizophrenia

• Participants who are unable to understand the study and therefore unable to provide informed consent

2. Pregnancy:

• Participants who are pregnant and/or breastfeeding

• Participants who are not willing to avoid pregnancy for themselves or their partners during the study by using effective birth control methods

3. Current medications:

• Participants taking a total daily dose of benzodiazepines greater than the equivalent of 6mg/day of lorazepam

• Participants on complementary and alternative medicine therapies i.e., St John's wort, Chinese medicines, and various herbal and homeopathic treatments

4. Stimulants

• Participants taking stimulants such as methylphenidate, amphetamine, and dextroamphetamine for a diagnosis such as ADHD can still have Esketamine provided they do not continue taking stimulants concurrently for the duration of the study.

• Concurrent use is excluded due to the synergistic effect with Esketamine that can cause increased blood pressure.

5. Medical history:

• Participants with current or past history of seizures (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)

• Participants with a history of uncontrolled hypertension

• Participants with uncontrolled diabetes mellitus

• Participants with aneurysmal vascular disease including thoracic and abdominal aorta, intracranial and peripheral arterial vessels, or arteriovenous malformation, intracerebral haemorrhage

• Participants with untreated glaucoma, current penetrating or perforating eye injury, brain injury, hypertensive encephalopathy, intrathecal therapy with ventricular shunts, or any other condition associated with increased intracranial pressure or increased intraocular pressure or planned eye surgery

• Participants who are currently receiving electroconvulsive therapy (ECT) or have received ECT in the past month.

6. Substance Misuse History:

• Participants who have ever had a substance misuse disorder involving any of the following over their lifetime: ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-methamphetamine (MDMA), or other hallucinogen use history

• Participants with hypersensitivity to Esketamine, Ketamine, or any of the excipients

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Esketamine Nasal Spray [Spravato]
This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

Locations

Country	Name	City	State
Australia	Royal North Shore Hospital	St Leonards	New South Wales

Sponsors (2)

Lead Sponsor	Collaborator
Royal North Shore Hospital	Janssen-Cilag Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of treatment responders determined by a 50% reduction on the Hamilton Depression Rating Scale (HAM-D) 17-Item scoring.	Hamilton Depression Rating Scale (HAM-D) 17-Item scoring	At the end of week 4
Primary	Mean depression score on the Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.	Quick Inventory of Depressive Symptomatology Self-report (QIDS-SR) 16-Item.	Baseline, at the end of weeks 1,2,3, and 4 (primary time point); and further after week 8 and week 12 after Esketamine was commenced.
Primary	Global functioning determined by Clinical Global Impression (CGI) score.	Clinical Global Impression (CGI)	Baseline, week 1, week 2, week 3, week 4 (primary time point), week 8 and week 12 after Esketamine was commenced.
Secondary	Change in mood symptom scores assessed using the visual analogue scale (self-reported)	Visual analogue scale (self-reported)	Baseline, after treatment day 1 and day 3 of each week until Esketamine is ceased.
Secondary	Depressive symptoms assessed using the Beck Depression Inventory (BDI) 21-Item.	Beck Depression Inventory (BDI) 21-Item.	Baseline and at week 4 after Esketamine was commenced.
Secondary	Anxiety symptoms assessed using the State-Trait Anxiety Inventory (STAI)	State-Trait Anxiety Inventory (STAI)	Baseline and at week 4 after Esketamine was commenced.